Figure 3 | Scientific Reports

Figure 3

From: Safety and efficacy of oral administrated cepharanthine in non-hospitalized, asymptomatic or mild COVID-19 patients: a Double-blind, randomized, placebo-controlled trial

Figure 3

Subgroup analysis of the difference in the time to negative nasopharyngeal swab compared to placebo (mITT). Panel A shows the subgroup analysis of between patients who received 60 mg/day of CEP and those who received placebo. Panel B shows the subgroup analysis between patients who received 120 mg/day of CEP and those who received placebo.

Back to article page